UK: Life Sciences Issues In Corporate Transactions – Part 2

Last Updated: 17 June 2016
Article by Colin McCall
Most Read Contributor in UK, January 2017

In the second part to 'Life Sciences issues in corporate transactions', published in the January edition of Synapse, Colin McCall discusses the development cycle and the patent cliff and other matters important to the life science sector, including biosimilars, orphan medicines, parallel imports and compulsory licences.

THE DEVELOPMENT CYCLE AND THE PATENT CLIFF

Intellectual property protection is vital to maximising the benefit of R&D in the life sciences. Technological improvements, especially when embodied in commercial products, tend to be fairly transparent and therefore available to potential competitors. Such competitors can therefore acquire knowledge about new medicinal products within a reasonably short period of time and with a relatively modest R&D effort of their own.

In order to understand the benefit of IP protection and the effect of the 'patent cliff', an understanding of the development cycle of a successful medicinal product is important. Early phases in the development cycle, such as discovery and preclinical and clinical phases are typically characterised by initially low but rapidly increasing improvements in the medicinal product (eg, preferred formulations, efficient manufacturing processes, new indications, dosing regimen, etc) as development issues are ironed out, but accompanied by negative total revenue given the huge costs associated with discovery and clinical development. During the intermediate phases of post-marketing approval and then peak sales improvements become increasingly hard to achieve but revenues rapidly increase. In the later stages of generic competition and commoditisation little or no performance improvements are possible and revenues in respect of the product diminish.

In Figures 1 and 2 the columns each represent a phase during the development cycle: A = research (ie, discovery); B = preclinical and clinical phase; C = post-marketing approval; D = peak sales; E = generic competition/product substitution; and F = fully commoditised/obsolescence.


The time at which competition occurs is known as the patent cliff and will depend entirely on the strength of the IP portfolio the initial developer has managed to acquire. When the patent cliff is reached, the revenues available to all market entrants in respect of the product rapidly collapse. But it is the patent holder that loses most. By way of example, the best-selling drug in history, Pfizer's Lipitor had peak sales of around $11 billion per annum in 2009 and 2010 before going off patent in 2011. Since then Pfizer's sales of Lipitor collapsed to $2 billion for 2013. Indeed, in the last five years according to an IMS report1 the patent cliff has caused losses in revenue to innovator pharmaceutical companies of $154 billion.

The costs/revenues shown in the development cycle curve in Figure 1 represent the costs/revenues spent or achieved by all market entrants in respect of a given medicinal product as a whole and not just the costs/revenue of the first life sciences company to develop the new medicinal product. It will be the first developer that incurs almost all of the cost and derives almost all of the revenue up until the patent cliff. Thereafter, the revenues are shared by all market entrants.

The longer a life sciences company can prevent competition and delay the patent cliff, the longer it can prevent price erosion and the greater the proportion of the available revenues from a particular product it can keep for itself. In order for life sciences companies to weather the storm of patent cliff faces they must continually bring new medicinal products to market through a development pipeline. Historically these pipelines have been derived through internal R&D efforts, but increasingly, larger life sciences companies are seeking to bolster their development pipeline with the acquisition of smaller-cap life sciences companies with late-stage development products through corporate transactions or through in-licensing deals. Accordingly, early-stage life sciences companies that have broad IP protection in respect of their core technologies are much more attractive investment propositions.

OTHER MATTERS OF IMPORTANCE IN THE LIFE SCIENCE SECTOR

Biosimilars

Improvements in technology and pressures to diversify business models away from small molecule drugs are just two of the factors that are focusing attention on biological medicinal products (ie, medicinal products that are made by a living organism, such as a bacterium or yeast and can consist of relatively small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies). This has led to a rise in biosimilars.

Biosimilars are biological medicinal products that are similar to another biological product that has already been authorised and that do not differ significantly from the original product in terms of quality, safety and efficacy. As such, biosimilars are copies of biological medicines that are already approved.

There is no formal definition of 'biosimilar' in European legislation and the term biosimilar should not be confused with the terms 'biobetter' and 'me-too biologic'.

A biobetter is a biological product that has been altered structurally or functionally to improve its performance. A me-too biologic is a biological medicine that targets the same pathway but is developed independently of a reference biological and is not compared to it. Neither a biobetter nor a me-too biologic can be authorised using the biosimilar route.

An applicant for approval of a biosimilar product under the biosimilar route is required to demonstrate that its product is similar to a previously authorised product. The application for approval can reference data submitted for the previously authorised product after the expiry of the data exclusivity period.

However, the use of the term 'similar' reflects the scientific reality that biological products cannot be copied precisely. Biological products are much larger and more complex than chemical pharmaceutical compounds and are produced in sensitive biological systems that can be affected by small changes in process conditions. Controlling the production of biological products, in particular any post-translational modifications, is therefore challenging. So, while it is possible to control precisely the production of generic chemical pharmaceutical compounds and to authorise them using an abridged procedure on the basis of bioequivalence data, this is not possible with biological products.

Data over and above the standard tests required for small molecule generics will therefore normally be required in order to demonstrate that a biosimilar is comparable to the reference biologic product. As a general rule, the biosimilar route requires more extensive testing and, most likely, clinical trials (which are not needed for small molecule generic drugs).

Orphan medicines

Since the pharmaceutical industry has fewer incentives, under normal market conditions, in developing and marketing medicinal products intended for rare diseases that by definition will only be used to treat small numbers of patients, the EU offers a range of incentives to encourage the development of these medicinal products – known as orphan medicines.

For a medicinal product to be classed as an orphan medicine, it must be intended for the diagnosis, prevention or treatment of either:

  • a life-threatening or chronically debilitating condition affecting no more than 5 in 10,000 people in the EU at the time of submission of the application for orphan designation; or
  • a life-threatening, seriously debilitating or serious and chronic condition where, without incentives, it would be unlikely that the revenue after marketing of the medicinal product would cover the investment in its development.

There must also be either no satisfactory method of diagnosis, prevention or treatment of the condition concerned, or, if there is such a method, the new medicine must be of significant benefit to those affected by the condition.

The principal benefit for medicinal products designated as orphan medicines is that they benefit from more generous treatment as regards market exclusivity, namely:

  • a period of 10 years from the date of marketing authorisation, which may run in parallel with the basic marketing exclusivity if the drug is also authorised (via a separate marketing authorisation) for other indications;
  • any additional orphan indications for the same product will also benefit from their own separate 10-year period of market exclusivity; and
  • where an application for a marketing authorisation for an orphan product includes the results of studies conducted in accordance with an agreed PIP, the 10-year period is extended to a period of 12 years.

Parallel imports

Parallel import regime in Europe

Parallel importation of medicinal products in the EEA relies on the principle of patent exhaustion, which itself arises from the EU's and also the EEA's treaty commitments to the free movement of goods. These freedom of movement of goods rules as regards patented medicinal products were first established in 1974 in the case of Centrafarm BV v Sterling Drug Inc2 and dictate that when a patent/SPC holder puts (or consents to the putting of) a medicinal product on the market anywhere in the EEA, the patent/SPC holder cannot object to a purchaser of those products subsequently putting them on the market in a different EEA member state, regardless of whether such import into a subsequent EEA member state would infringe the patent/SPC holder's national patent/SPC rights in the member state of destination. As a result of the differences in prices set by national governments and also by the patent/SPC owners themselves in the various different EEA states there is now a significant volume of parallel import activity.

The parallel import of medicinal products is, however, subject to significant regulation. The importer still requires a licence to import and market the product in the member state of destination, and the product packaging must meet the requirements of the member state of destination.

Parallel import licences

A parallel imported medicinal product may be distributed under an authorisation obtained through a simpler procedure than that for the initial marketing authorisation for the product. To qualify for the simplified procedure, the parallel imported medicinal product must satisfy two conditions. It must:

  • have been granted a marketing authorisation in the member state of origin; and
  • be sufficiently similar to a product that has already received marketing authorisation in the member state of destination.

The similarity between two medicinal products is considered to be sufficient when the two products have been manufactured according to the same formulation, using the same active ingredient, and have the same therapeutic effects. A parallel imported medicinal product can also be distributed under the simplified procedure even if the similar product upon which its licence is based is no longer available on the market, provided that public health requirements are met.

Repackaging of parallel imports

Repackaging will be necessary if the packaging sizes in use in the member state of origin are not permitted in the member state of destination. In principle, however, this is precluded by the trademark right of the manufacturer since all changes to the packaging or the product itself will constitute an infringement of the manufacturer's trademark. But this rule conflicts with the principle of the free movement of goods within the EEA. The case of Bristol-Myers Squibb3 has therefore ruled that certain necessary and appropriate changes are permitted, if they are made in order to eliminate obstacles in the distribution process. The so-called BMS Conditions are:

  • the use of the trademark right by the owner contributes to the artificial partitioning of the internal market;
  • the repackaging does not adversely affect the original condition of the product;
  • it is stated on the new packaging by whom the product has been manufactured and by whom it has been repackaged;
  • the presentation of the repackaged product is not such as to damage the reputation of the trademark or of its proprietor; and
  • the proprietor of the trademark receives written notice of the repackaging before the new product is put on sale and in addition, if he requests it, is supplied with a specimen of the repackaged product upon demand.

The repackaging must be necessary, and not just motivated by commercial interests. For example, repackaging is not justified for a parallel imported product that may be put on sale in the member state of destination simply by changing the labelling of the outer packaging (eg, language matters).

Compulsory licences

The availability of compulsory licences in respect of patents, especially in relation to pharmaceutical patents, has been the subject of considerable attention lately. This is mainly as a result of the Indian courts showing their willingness to grant compulsory licences in respect of pharmaceutical patents. In particular, the Indian courts recently granted a compulsory licence to an Indian generic pharmaceutical company under Bayer's patent for its cancer drug Nexavar, determining that in essence Bayer's price for Nexavar was too high. This, together with Bayer's failed challenge that India's patent legislation under which the compulsory licence was granted was not compliant with the Agreement on Trade-Related Aspects of Intellectual Property Rights (the TRIPS agreement puts restrictions on the ability of World Trade Organization members (of which India is one) to restrict the exclusive rights of patentees through – among other things – compulsory licences), has led to significant media interest in the power under national patent legislation to grant compulsory patent licences.

Article 31 of the TRIPS agreement provides that where patent legislation of World Trade Organization member states allows compulsory licences to be granted the following provisions must be included:

  • Each case must be decided on its own merits.
  • The applicant for the compulsory licence must have made efforts to take a licence from the patentee on reasonable commercial terms.
  • The scope and duration of the compulsory licence must be limited to the purpose for which it was granted, such that it may be terminated or amended if the circumstances that led to the grant of the compulsory licence change or cease to exist.
  • The patentee must be paid adequate remuneration for use under the compulsory licence.
  • The decision to grant a compulsory licence and the determination of what is adequate remuneration shall be subject to judicial review.
  • Where a compulsory licence is granted in order to enable a second patent to be exploited, the invention claimed in the second patent must involve an important technical advance of considerable economic significance in relation to the invention claimed in the first patent and the patentee of the first patent must be entitled (on reasonable terms) to a cross-licence in respect of the second patent.

This article is an extract from the Life Sciences chapter of Intellectual Property Issues in Corporate Transactions, published by Globe Law and Business, December 2015.

Footnotes

1. Report by the IMS Institute for Healthcare Informatics, Global Outlook for Medicines Through 2018, November 2014.

2. 15/74.

3. Joined cases C-427/93, C-429/93 and C-436/93.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.